Authors:
Xia LuDepartment of Nuclear Medicine, Peking University First Hospital, No. 8, Xishiku St., West District, Beijing, 100034 People’s Republic of China

Search for other papers by Xia Lu in
Current site
Google Scholar
PubMed
Close
,
Ping YanDepartment of Nuclear Medicine, Peking University First Hospital, No. 8, Xishiku St., West District, Beijing, 100034 People’s Republic of China

Search for other papers by Ping Yan in
Current site
Google Scholar
PubMed
Close
,
Rongfu WangDepartment of Nuclear Medicine, Peking University First Hospital, No. 8, Xishiku St., West District, Beijing, 100034 People’s Republic of China

Search for other papers by Rongfu Wang in
Current site
Google Scholar
PubMed
Close
,
Meng LiuDepartment of Nuclear Medicine, Peking University First Hospital, No. 8, Xishiku St., West District, Beijing, 100034 People’s Republic of China

Search for other papers by Meng Liu in
Current site
Google Scholar
PubMed
Close
,
Mingming YuDepartment of Nuclear Medicine, Peking University First Hospital, No. 8, Xishiku St., West District, Beijing, 100034 People’s Republic of China

Search for other papers by Mingming Yu in
Current site
Google Scholar
PubMed
Close
,
Chunli ZhangDepartment of Nuclear Medicine, Peking University First Hospital, No. 8, Xishiku St., West District, Beijing, 100034 People’s Republic of China

Search for other papers by Chunli Zhang in
Current site
Google Scholar
PubMed
Close
, and
Fengqing GuoDepartment of Nuclear Medicine, Peking University First Hospital, No. 8, Xishiku St., West District, Beijing, 100034 People’s Republic of China

Search for other papers by Fengqing Guo in
Current site
Google Scholar
PubMed
Close
View More View Less
Restricted access

Abstract  

The importance of angiogenesis in tumor growth and metastasis has led to develop new imaging tracers to understand angiogenic vasculature. Based on the previous study, we further focused on the tumor molecular imaging application of the novel peptide Arginine-Arginine-Leucine (Tyr-Cys-Gly-Gly-Arg-Arg-Leu-Gly-Gly-Cys, tRRL) in this study. The cytotoxicity of raioiodinated tRRL (131I-tRRL) in HepG2 cells was assessed by tested cell viability using kit. tRRL was conjugated with fluorescein FITC to observe its binding with tumor cells and human aortic endothelial cells (HAEC) in vitro. Whole body SPECT imaging of varied tumors xenograftes was performed after intravenous injection of 131I-tRRL for 24 h in BALB/c nude mice. Compared with negative control PBS, small peptide tRRL was of non-cytotoxicity. 131I-tRRL could lead to significant cytotoxicity on HepG2 cells when the radioactivity was greater than 370 kBq. In vitro binding experiment and cellular uptake results revealed that tRRL could adhere to tumor cells besides tumor derived endothelial cells. In vivo SPECT imaging, 131I-tRRL mainly accumulated in various tumor tissues, including melanoma, liver cancer and lung cancer bearing mice. In breast cancer xenografte imaging, the tumor has no significant radionuclide accumulation at 24 h after injected of 131I-tRRL. Radioiodinated tRRL offers a noninvasive nuclear imaging method for functional molecular imaging of tumors, and may be a promising candidate carrier for tumor targeted therapy.

  • Collapse
  • Expand

To see the editorial board, please visit the website of Springer Nature.

Manuscript Submission: HERE

For subscription options, please visit the website of Springer Nature.

Journal of Radionalytical and Nuclear Chemistry
Language English
Size A4
Year of
Foundation
1968
Volumes
per Year
1
Issues
per Year
12
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Springer Nature Switzerland AG
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0236-5731 (Print)
ISSN 1588-2780 (Online)